Terminology Service for NFDI4Health

Rigosertib Sodium

Go to external page http://purl.obolibrary.org/obo/NCIT_C71355


A synthetic benzyl styryl sulfone analogue with potential antineoplastic activity. Polo-like kinase 1 inhibitor ON 01910.Na inhibits polo-like kinase1 (Plk1), inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. [ ]

Term info

Label

Rigosertib Sodium

Synonyms
  • ON 01910.Na
  • Polo-like kinase 1 Inhibitor ON 01910.Na
  • RIGOSERTIB SODIUM
  • Rigosertib Sodium
Subsets

NCIT_C116978, NCIT_C63923, NCIT_C128784, NCIT_C157711, NCIT_C116977, NCIT_C157712

ALT DEFINITION

A substance being studied in the treatment of cancer. It blocks certain proteins that are needed for cell growth and may kill cancer cells. ON 01910.Na is a type of protein kinase inhibitor and a type of benzyl styryl sulfone analog.

CAS Registry

592542-60-4

Chemical Formula

C21H24NO8S.Na

Display Name

Rigosertib Sodium

FDA UNII Code

406FL5G00V

Has Target

http://purl.obolibrary.org/obo/NCIT_C30006

Legacy Concept Name

Polo-like_kinase_1_Inhibitor_ON_01910_Na

Preferred Name

Rigosertib Sodium

Semantic Type

Pharmacologic Substance

UMLS CUI

C3467794

code

C71355